Novartis AG is 55.6x more valuable than Apellis Pharmaceuticals, Inc. by market capitalization ($292.08 B vs $5.25 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | APLS | NVS |
|---|---|---|
| Market cap | $5.25 B | $292.08 B |
| US-listed rank | #1370 | #47 |
| Revenue (latest FY) | $1.00B | - |
| Net income (latest FY) | $22.39M | - |
| Net margin | 2.2% | - |
| P/E (trailing FY) | 234.6 | - |
| SEC filings | 1,217 | 947 |
Novartis AG is 55.6x more valuable than Apellis Pharmaceuticals, Inc. by market capitalization ($292.08 B vs $5.25 B).
Full pages: Apellis Pharmaceuticals, Inc. and Novartis AG, or browse the full rankings.